ELOX revenueFY2025$0
- FY YoY
- -100.0%
ELOX revenue was $0 for fiscal 2025 (ended Dec 31, 2025), down 100.0% from fiscal 2024.
Eloxx Pharmaceuticals Inc. (ELOX) financials
For fiscal 2025 (ended Dec 31, 2025), Eloxx Pharmaceuticals Inc. reported $0 of revenue and -$6.00M of net income.
- Revenue, FY2025
- $0
- Revenue growth, YoY
- -100.0%
- Net income, FY2025
- -$6.00M
- EPS, diluted, FY2025
- -$0.49
- Cash
- $61.96M
- Market cap
- $54.5M
FY2014FY2025
FY2014FY2025
FY2014FY2022
ELOX revenue and earnings growth
ELOX net incomeQ2 2026-$4.50M
ELOX net income was -$4.50M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$1.89M a year earlier. For the full fiscal 2025 it was -$6.00M, compared with -$3.14M in fiscal 2024.
ELOX EPSQ2 2026-$0.66
ELOX diluted EPS was -$0.66 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$0.49.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Jun 30, 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $6.36M | $0 | - | - | - | - | - | - | $182.2K |
| Research and development | $3.06M | $3.58M | $8.60M | $23.73M | $22.90M | $14.59M | $26.35M | $20.49M | $16.40M | $3.34M |
| Selling, general and admin | $3.38M | $5.25M | $8.69M | $10.69M | $20.45M | $14.85M | $24.21M | $26.48M | $2.70M | $3.68M |
| Operating income | -$6.44M | -$2.47M | -$17.29M | -$34.42M | -$66.02M | -$33.45M | -$50.55M | -$47.56M | -$20.39M | -$9.15M |
| Pre-tax income | -$6.00M | -$3.14M | -$17.05M | -$36.06M | -$66.73M | -$34.58M | -$50.87M | -$47.06M | -$21.21M | -$9.23M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $122.0K | - | $0 |
| Net income | -$6.00M | -$3.14M | -$17.05M | -$36.06M | -$66.73M | -$34.58M | -$50.87M | -$47.19M | -$21.21M | -$9.23M |
| EPS, basic | -$0.49 | -$0.84 | -$6.63 | -$666.00 | -$1526.00 | -$34.40 | -$53.60 | -$58.00 | -$190.00 | -$101.20 |
| EPS, diluted | -$0.49 | -$0.84 | -$6.63 | -$666.00 | -$1526.00 | -$34.40 | -$53.60 | -$58.00 | -$190.00 | -$101.20 |
| Diluted shares | 12.3M | 3.8M | 2.6M | 54,157.775 | 43,726.775 | 1.0M | 951,579.325 | 810,912.65 | 124,409.425 | 136,917.925 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Jun 30, 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $4.79M | $111.0K | $1.13M | $19.21M | $42.27M | $24.67M | $22.49M | $48.61M | $24.05M | $6.11M |
| Receivables | - | - | - | - | - | - | - | - | - | $43.1K |
| Current assets | $5.27M | $2.98M | $1.55M | $20.13M | $43.48M | $25.89M | $57.71M | $50.34M | $24.51M | $7.22M |
| Goodwill | - | - | - | - | - | - | - | - | - | $13.90M |
| Total assets | $5.27M | $2.98M | $1.71M | $21.12M | $45.14M | $26.48M | $58.95M | $50.72M | $24.78M | $33.33M |
| Current liabilities | $17.18M | $27.31M | $22.70M | $23.09M | $9.96M | $9.84M | $11.81M | $7.81M | $3.42M | $1.83M |
| Short-term debt | $1.00M | $6.52M | $2.22M | $3.98M | $0 | $5.24M | $4.34M | - | - | - |
| Long-term debt | $0 | $0 | $1.61M | $8.56M | $12.00M | $6.38M | $10.50M | - | - | - |
| Total debt | $1.00M | $6.52M | $3.83M | $12.54M | $12.00M | $11.62M | $14.84M | - | - | - |
| Total liabilities | $17.18M | $27.31M | $24.31M | $31.78M | $22.75M | $16.25M | $22.73M | $7.81M | - | $5.84M |
| Shareholders' equity | -$11.91M | -$24.34M | -$22.60M | -$10.66M | $22.38M | $10.23M | $36.21M | $42.91M | $21.36M | $27.49M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Jun 30, 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6.33M | -$4.71M | -$14.34M | -$31.84M | -$35.00M | -$28.17M | -$39.39M | -$31.37M | -$15.94M | -$4.87M |
| Capital expenditures | - | - | - | $66.0K | $89.0K | - | $40.0K | $235.0K | $237.0K | $3.2K |
| Free cash flow | - | - | - | -$31.91M | -$35.09M | - | -$39.43M | -$31.60M | -$16.17M | -$4.87M |
| Investing cash flow | $1.0K | $38.0K | $309.0K | -$66.0K | $2.06M | $33.79M | -$33.52M | -$317.0K | -$114.0K | $646.9K |
| Financing cash flow | $11.00M | $3.44M | -$4.08M | $8.81M | $50.79M | -$3.44M | $46.80M | $56.18M | $37.95M | $8.73M |
| Dividends paid | - | - | - | - | - | - | $0 | $0 | $0 | - |
| Stock-based compensation | $235.0K | $541.0K | $1.97M | $3.02M | $9.17M | $8.67M | $11.34M | $13.37M | $101.0K | $1.30M |
| Depreciation and amortization | - | - | - | - | - | - | - | - | - | $349.7K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Jun 30, 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -100.0% | - | - | - | - | - | - | - | - | 2230.6% |
| Operating margin | - | -38.8% | - | - | - | - | - | - | - | -5019.9% |
| Net margin | - | -49.4% | - | - | - | - | - | - | - | -5062.4% |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | -2673.2% |
| Return on equity | - | - | - | - | -298.1% | -338.0% | -140.5% | -110.0% | -99.3% | -33.6% |
| Return on assets | -113.8% | -105.6% | -996.1% | -170.7% | -147.8% | -130.6% | -86.3% | -93.0% | -85.6% | -27.7% |
| Current ratio | 0.31 | 0.11 | 0.07 | 0.87 | 4.37 | 2.63 | 4.89 | 6.45 | 7.16 | 3.96 |
| Debt to equity | - | - | - | - | 0.54 | 1.14 | 0.41 | - | - | - |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $2.84M | $1.66M | $898.0K | $510.0K | $1.52M | $1.25M | $2.34M | $3.49M | $3.30M | $4.88M | $7.65M | $7.90M |
| Selling, general and admin | $1.61M | $2.14M | $684.0K | $712.0K | $2.51M | $2.39M | $1.80M | $2.00M | $2.73M | $2.26M | $2.65M | $3.05M |
| Operating income | -$4.45M | -$3.79M | -$1.58M | -$1.22M | -$4.03M | -$3.64M | -$4.14M | -$5.48M | -$6.03M | -$7.14M | -$10.30M | -$10.95M |
| Net income | -$4.50M | -$3.75M | -$1.89M | -$1.71M | -$2.89M | -$3.59M | -$4.34M | -$6.23M | -$6.32M | -$7.51M | -$10.62M | -$11.62M |
| EPS, basic | -$0.66 | -$0.08 | -$5.45 | -$0.45 | - | -$1.31 | -$1.96 | -$115.20 | - | -$3.47 | -$4.90 | -$214.40 |
| EPS, diluted | -$0.66 | -$0.08 | -$5.45 | -$0.45 | - | -$1.31 | -$1.96 | -$115.20 | - | -$3.47 | -$4.90 | -$214.40 |
| Diluted shares | 6.8M | 48.2M | 347,000 | 3.8M | - | 2.7M | 2.2M | 54,158.9 | - | 2.2M | 2.2M | 54,156.875 |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $61.96M | $6.36M | $572.0K | $450.0K | $1.13M | $4.78M | $4.33M | $4.90M | $19.21M | $24.55M | $30.05M | $39.77M |
| Current assets | $63.39M | $8.50M | - | - | $1.55M | $5.63M | $5.38M | $6.40M | $20.13M | $25.67M | $31.59M | $42.15M |
| Total assets | $63.39M | $8.50M | - | - | $1.71M | $6.04M | $5.99M | $7.20M | $21.12M | $26.88M | $32.94M | $43.62M |
| Current liabilities | $16.97M | $16.09M | - | - | $22.70M | $23.47M | $21.25M | $19.46M | $23.09M | $21.68M | $19.50M | $19.17M |
| Short-term debt | $0 | $0 | - | - | $2.22M | $2.82M | $2.28M | $1.54M | $3.98M | $2.53M | $1.13M | - |
| Long-term debt | - | - | - | - | $1.61M | $2.62M | $3.33M | $4.03M | $8.56M | $9.86M | $11.13M | $12.12M |
| Total debt | - | - | - | - | $3.83M | $5.44M | $5.61M | $5.56M | $12.54M | $12.39M | $12.25M | $12.12M |
| Total liabilities | - | - | - | - | $24.31M | $26.09M | $24.59M | $23.49M | $31.78M | $31.86M | $31.13M | $31.93M |
| Shareholders' equity | $46.42M | -$7.58M | -$27.90M | -$26.02M | -$22.60M | -$20.05M | -$18.60M | $16.29M | -$10.66M | -$4.98M | $1.81M | $11.69M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.79M | -$5.45M | -$1.75M | $1.20M | -$2.01M | -$3.45M | -$2.07M | -$6.81M | -$5.66M | -$6.95M | -$9.75M | -$9.49M |
| Capital expenditures | - | - | - | - | - | $0 | $0 | $0 | $0 | $48.0K | $7.0K | $11.0K |
| Free cash flow | - | - | - | - | - | -$3.45M | -$2.07M | -$6.81M | -$5.66M | -$6.99M | -$9.75M | -$9.50M |
| Investing cash flow | - | - | - | - | $51.0K | $233.0K | $14.0K | $11.0K | $0 | -$48.0K | -$7.0K | -$11.0K |
| Financing cash flow | $60.39M | $7.03M | $1.88M | -$865.0K | -$1.68M | $3.67M | $1.43M | -$7.50M | $312.0K | $1.50M | $0 | $7.00M |
| Stock-based compensation | $95.0K | $46.0K | $16.0K | $20.0K | $340.0K | $418.0K | $610.0K | $597.0K | $641.0K | $714.0K | $744.0K | $922.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 3.74 | 0.53 | - | - | 0.07 | 0.24 | 0.25 | 0.33 | 0.87 | 1.18 | 1.62 | 2.20 |
| Debt to equity | - | - | - | - | - | - | - | 0.34 | - | - | 6.76 | 1.04 |
Source: XBRL data Eloxx Pharmaceuticals Inc. files with the SEC, latest filing dated Aug 11, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-40, first reported Aug 11, 2023.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
ELOX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| ELOX | $0 | -100.0% | -$6.00M | - | $54.5M |
| SUPN | $1.37B | +16.3% | $450.00M | 32.8% | $3.26B |
| ZYME | $265.97M | +97.8% | $43.31M | 16.3% | $2.17B |
| ANIP | $1.04B | +25.9% | $116.84M | 11.2% | $1.54B |
ELOX FAQ
7 questionsWhat is ELOX revenue?
Eloxx Pharmaceuticals Inc. (ELOX) reported $0 of revenue for fiscal 2025 (ended Dec 31, 2025). That is down 100.0% from the year before.Is ELOX profitable?
No. Eloxx Pharmaceuticals Inc. reported a net loss of $6.00M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does ELOX have?
Eloxx Pharmaceuticals Inc. reported $61.96M in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is ELOX revenue growing?
Eloxx Pharmaceuticals Inc.'s revenue changed -100.0% in fiscal 2025, to $0.What is ELOX earnings per share?
Diluted earnings per share were -$0.49 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did ELOX last report financial results?
The latest statements here come from Eloxx Pharmaceuticals Inc.'s 10-Q filed on Aug 11, 2026, covering the period ended Jun 30, 2026.Where does this ELOX financial data come from?
Quantisnow builds these statements from the structured XBRL data Eloxx Pharmaceuticals Inc. files with the SEC. It is provided for information only and is not investment advice.